SCHEMBL3605625

SCHEMBL3605625

O=C(Cn1ccc2cccc(-c3ccc(C(F)(F)F)cc3)c21)NCCNCC1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.38
MAPK1 P28482 2/20 0.37
HTT P42858 2/20 0.37
PIM1 P11309 1/20 0.37
USP2 O75604 1/20 0.37
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
MLYCD O95822 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
ALDH1A1 P00352 2/20 0.36
KCNQ3 O43525 1/20 0.36
KCNQ2 O43526 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MDM2 Q00987 1/20 0.36
NPY5R Q15761 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CCR2 P41597 1/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3608260 0.90 GRIN2B (0.42) MAPK1HTTLMNASMN1; SMN2ALDH1A1
SCHEMBL3597289 0.89 ALDH1A1 (0.41) MAPK1HTTLMNASMN1; SMN2ALDH1A1
SCHEMBL3594707 0.88 NPC1 (0.41) MAPK1HTTLMNASMN1; SMN2ALDH1A1
SCHEMBL3589653 0.88 ROCK2 (0.38) MAPK1HTTLMNASMN1; SMN2ALDH1A1
SCHEMBL3608180 0.88 HTT (0.45) MAPK1HTTLMNASMN1; SMN2ALDH1A1
SCHEMBL3605921 0.86 EPHX2 (0.41) HTTSMN1; SMN2ALDH1A1NPY5RKDM4E
SCHEMBL3605994 0.85 PIM1 (0.42) MAPK1HTTPIM1ALDH1A1HSD17B10
SCHEMBL3606204 0.85 GRIN2B (0.41) MAPK1HTTLMNASMN1; SMN2HDAC6
SCHEMBL3605624 0.84 GAA (0.41) MAPK1HTTUSP2LMNASMN1; SMN2
SCHEMBL3589635 0.84 NPY5R (0.41) MAPK1HTTSMN1; SMN2ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807704-B2 Bicyclic, nitrogen-containing compounds modulating CXCR4 and/or CCXCKR2 CHEMOCENTRYX, INC. (US) 2010-10-05 US disclosed
US-20070275965-A1 CXCR4 modulators CHEMOCENTRYX, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275965-A1 CXCR4 modulators CXCL12, CXCR4, CXCR1 MGLL 4205/4885MAPK1 1264/4885HTT 1553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.